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Abstract
Background Loss of muscle mass and function is an important complication to ageing and a range of pathologies, including,
but not restricted to, cancer, organ failures, and sepsis. A number of interventions have been proposed ranging from exercise
to anabolic pharmacological therapy, with varying success. Easily applicable serological biomarkers of lean and/or muscle mass
and change therein would beneﬁt monitoring of muscle mass during muscle atrophy as well as during recovery. We set out to
validate if novel peptide biomarkers derived from Collagen III and VI were markers of lean body mass (LBM) or change therein
in head and neck cancer patients in the Danish Head and Neck Cancer Group(DAHANCA) 25B cohort subjected to resistance
training as well as in an age-matched and gender-matched control group.
Methods Blood samples and dual X-ray absorptiometry data were measured at baseline, after 12 and 24weeks in 41 HNSCC
subjects of the DAHANCA 25B cohort of subjects recovering from neck and head cancer (stages provided in Table 1), and at
baseline only in 21 healthy age-matched and gender-matched controls. Serum from blood was analyzed for the ProC3, IC6,
and C6M peptide biomarkers and LBM were derived from the dual X-ray absorptiometry scans.
Results We were not able to show any correlation between biomarkers and LBM or C6M and anabolic response to exercise
in recovering head and neck cancer patients. However, we did ﬁnd that the biomarkers IC6, IC6/C6M, and ProC3 are bio-
markers of LBM in the control group subjects (R2/P of 0.249/0.035, 0.416/0.007 and 0.178 and P = 0.057, respectively),
Conclusion In conclusion, the IC6, ProC3, and IC6/C6M biomarkers are indeed biomarkers of LBM in healthy individuals of
both genders, but not in HNSCC patients.
Keywords Muscle; Biomarker; Head and neck cancer; Resistance training
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Introduction
Identifying pathological loss of lean mass and particularly
muscle mass is an important task that may help target at-risk
individuals for proper therapeutic interventions. This calls for
development of novel early-response biomarkers of response
to treatment, as these could help establish efﬁcacy in clinical
trials of both pharmacological as well as physiotherapeutical
interventions.
Rapid muscle loss, cachexia (literally, ‘poverty of ﬂesh’), is a
serious complication to most cancer diseases1 and is a signif-
icant contributor to mortality and disability associated with
cancers.2,3 Cachexia-inducing pathologies that impact the
muscle mass do so through a number of endoparacrine and
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paracrine mechanisms. These combine to induce anorexia, di-
rect loss of muscle tissue, and resistance to anabolic stimuli
like feeding and exercise, resulting in a net loss of lean body
mass (LBM), predominantly muscle mass and strength, ulti-
mately and negatively impacting daily life and quality of life
of the patients.1,3 Loss of muscle mass may also manifest as
a consequence of treatment, for example, radiotherapy or
chemotherapy. This is particularly true for head and neck can-
cers, where the muscle loss is predominantly iatrogenic,
caused by anorexia and dysphagia secondary to mucositis of
the mouth and throat, caused by radiation therapy.2–5 This
may be compounded by catabolic effects of most cytotoxic
drugs used in combination with radiation therapy.6
Previous studies have shown that the serum levels of the
Collagen type III propeptide (ProC3) levels in serum correlate
well with LBM in young healthy men.7 As do the circulating
levels of Collagen type VI peptides containing the IC6 epi-
tope.8 In previous studies, we have shown that the anabolic
response to reloading following immobilization was inversely
related to the levels of the matrix-metalloproteinase (MMP)-
generated Collagen type VI fragment C6M.8 Both Collagen
types III and VI are known to be important constituents of
the extracellular matrix of skeletal muscle.9–11 Therefore,
fragments produced during muscle tissue turnover may
quantitatively reﬂect the gross turnover and thus correlate
with LBM. They could also be related to qualitative changes
in metabolism associated with distinct physiological or clinical
phenotypes, for example, fragments produced by a protease
upregulated by cancer chemokines.8
Head and neck squamous cell carcinoma (HNSCC)
patients have been shown to lose muscle mass as a con-
sequence of their pathology and treatment, and therefore,
they represent a physiological model in which muscle
mass is already perturbed, making the model a candidate
for muscle biomarker validation. Thus, in the present
study, we tested whether the previous ﬁndings pertaining
to the IC6 and ProC3 biomarkers could be reproduced or
expanded in a group of HNSCC patients as well as a group
of matched, healthy controls, both from the Danish Head
And Neck Cancer Group (DAHANCA)25B study.6,12 This is
a trial in which 41 HNSCC patients just after radiotherapy
and chemotherapy treatment course were subjected to
resistance training in order to restore muscle loss second-
ary to pathology or treatment. They were assigned to do
exercise either immediately following their last treatment
or 3months later.
Thus, the purpose of the present study was to validate or
expand our previous ﬁndings, i.e. (1) to conﬁrm if ProC3
and IC6 are useful biomarkers of LBM in a population of re-
covering HNSCC patients and to elucidate if ProC3 and IC6
are biomarkers of LBM in a group of age-matched and
gender-matched controls and (2) to investigate whether se-
rum C6M is a biomarker of change in LBM in HNSCC patients
subjected to resistance training.
Materials and methods
Setting and patients—head and neck squamous
cell carcinoma patients
The data from patients enrolled in the DAHANCA 25B trial were
included in this study. The DAHANCA 25B is a multicenter, ran-
domized trial investigating the effect of 12weeks of progressive
resistance training on LBM in HNSCC patients. This study was ap-
proved by the Ethics Committee for the Central Denmark Region
(id: 20110065), and the study was registered at clinicaltrials.gov
(identiﬁer: NCT01509430). All patients had completed radiother-
apy with or without chemotherapy with curative intent accord-
ing to the DAHANCA guidelines (www.dahanca.dk). Patients
were included from the oncological departments at Aarhus Uni-
versity Hospital and Odense University Hospital, and all testing
and blood sampling were conducted and repeated at the same
local facilities for each patient. Full details on treatment are pre-
sented elsewhere.6 Baseline data on body composition from 41
patients from the DAHANCA 25B trials were included (Table 1).
The subjects in the DAHANCA 25B trial were randomized and
did 12weeks of resistance training either immediately after com-
pletion of radiotherapy (early exercise, EE) or 12weeks are radio-
therapy (delayed exercise, DE). All executed the same 12week
progressive resistance training protocol.
Setting and patients—healthy individuals
Twenty-four healthy individuals were included in the DAHANCA
25B trial as controls. The recruitment of the healthy individuals
took place concurrently with the inclusion of patients in the orig-
inal DAHANCA 25B trial,6,12 and the procedure was conducted to
Table 1 Summary demographic data
Intervention group subjects
ControlsEE group DE group Pooled
n 20 21 41 21
Age (years) 55±7 58± 7 56±7 59±6
Gender (m/f) 17m/3f 19m/2f 36m/5f 14m/7f
Height (m) 1.75± 0.09 1.77±0.08 1.76±0.08 1.76±0.09
Weight (kg) 71.4± 17.2 73.9±9.6 72.7±13.7 76.3±13.2
BMI (kg/m2) 23.2± 4.1 23.6±3.0 23.4±3.6 24.4±3.1
LBM (kg) 52.1± 9.9 54.3±7.5 53.2±8.7 54.9±12.5
Cancer stages
1 3 (15%) 1 (5%) 4 (10%) NA
2 1 (5%) 3 (14%) 4 (10%) NA
3 2 (10%) 2 (10%) 4 (10%) NA
4 12 (60%) 10 (48%) 22 (54%) NA
ND 2 (10%) 5 (24%) 7 (17%) NA
Summary demographic data expressed as means± standard devia-
tions. Parts of these data have been published previously by Lønbro
et al.6 ND means cancer stage is not deﬁned for unknown primary
tumours. BMI, body mass index; LBM, lean body mass; EE, early ex-
ercise; DE, delayed exercise; NA, not applicable.
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match the population of HNSCC patients of the DAHANCA 25 tri-
als with respect to age, gender and socio-economic status. Thus,
asking all patients from the DAHANCA 25 trials to ﬁnd family
members, friends, or colleagues interested in participating pro-
vided twenty-four individuals. Three individuals were excluded
in the present paper because of lack of serum samples, leading
to a ﬁnal number of control subjects of 21. Participants fulﬁlled
the following inclusion criteria: (1) no current or previous malig-
nancies, psychological, social, or geographical conditions that
could prevent participation; (2) no self-reported excessive alco-
hol intake (men> 21 and women> 14 units/week); (3) no par-
ticipation in resistance training of more than 1h per week; and
(4) a written consent. All interested individuals were contacted
by telephone, and if they fulﬁlled the inclusion criteria, received
both written and oral information before giving written consent.
One of the interested individuals was excluded because of knee
problems. The healthy controls were only sampled once, and not
subjected to the resistance training protocol.
Resistance training protocol
The progressive resistance training protocol consisted of 30
sessions dispersed evenly over 12weeks in a local commer-
cial training facility. All patients received individual instruc-
tion 2–3 times during the initial ﬁve training sessions and
individual continuous follow-up as needed (3–7 times) during
the remaining training period. After two introductory training
sessions with two sets at a load corresponding to 15 repeti-
tions maximum (RM, e.g. 15 RM indicating the heaviest load
that can be lifted 15 times using proper technique), volume
and load progressed throughout the training period from
two sets of 12RM towards three sets of 8RM. For full details
on the training protocol, see Lønbro et al.13. When the
HNSCC patients were not assigned to resistance training, they
were advised to return to voluntary levels of physical activity.
The effects of the resistance training intervention have been
reported previously6 but are summarized for reference.
Changes described in the succeeding texts are for the deﬁned
periods, for example, from T1 to T2 or T2 to T3. During the T1
and T2 periods, the EE group increased their LBM by 4.3%
± SD (2.3 kg; P< 0.001; 95% CI 1.7; 3.0) after the resistance
training, which was 1.5 ± 0.5 kg larger (P = 0.005; 95% CI 0.5;
2.5) than the 1.5% change in the DE group after a 12-week
period of self-chosen physical activity. During the T2 and T3
periods, the DE group, LBM, increased by 4.2% ± SD (2.4 kg;
P< 0.001; 95% CI 1.1; 3.1) after resistance training (during
the T2 and T3 periods), which was 2.1 ± 0.5 kg larger
(P< 0.001; 95% CI 1.1; 3.1) than the 0.5% change in EE after
self-chosen physical activity during the same period. In sum-
mary, an overall increase of approximately 4% in LBM was
seen after resistance training irrespective of whether training
was performed early or late.
Sampling
The control subjects and both intervention groups were dual
X-ray absorptiometry (DXA)-scanned and had blood drawn at
baseline, designatedas T1. The interventiongroupswere scanned
and had blood drawn also at the 12-week time point, designated
as T2, and the ﬁnal 24-week time point, designated as T3.
Body composition
Whole body LBM was evaluated using DXA with narrow fan
beam technology (Aarhus site: Lunar Prodigy Advance, GE
Healthcare Technologies, Madison, WI, USA; Odense site:
Hologic QDR-Series, Hologic Inc., Bedford, MA, USA). The pro-
vided LBM is without bone mass.
Biomarker assays
All biomarker assays were competitive ELISA assays based on
proprietary antibodies against the relevant peptides. The as-
says have previously been described.7,8,14 The reported
intra-assay and inter-assay coefﬁcients of variations (CVs)
are for ProC3: 4.11 and 11.03%; for IC6: 11.1 and 11.8%; and
for C6M: 4.1 and 10.1%.7,8,14 Each ELISA assay was conducted
as follows: Streptavidin-coated 96-well ELISA plates were in-
cubated with a biotinylated coater in 100μL coating buffer
for 30min at 20°C on a shaker (at 300 rpm). Next, the plate
was incubated with 20μL of sample or standard/calibrator
and 100μL of HRP-conjugated monoclonal antibody diluted
in Ab incubation buffer for a deﬁned period of time in a
ﬁxed-temperature cabinet. After each incubation step, the
plate was washed ﬁve times in washing buffer (20mM Tris,
50mM NaCl, pH 7.2). Finally, 100μL tetramethylbenzinidine
(TMB) (Kem-En-Tec cat. no. 438OH) was added and the plate
was incubated for 15min at 20°C in the dark. The TMB reac-
tion was stopped by adding 100μL stopping solution (1%
H2SO4) and measured spectrophotometrically at 450 nm with
650 nm as the reference. Standard curves were generated by
serial dilution of the calibrator peptide in each assay, pipetted
on every plate and automatically ﬁtted using a four-parameter
ﬁt (y = (AD)/(1 + (x/C^B) + D)) model in Softmax Pro version 5
(Molecular Devices, Sunnyvale, CA, USA). These ﬁts were used
to calculate biomarker levels through curve regression.
Statistical analysis
Initial analysis of the data revealed that the biomarker data
were non-normally distributed and displayed an upward
skew characteristic of many biological traits, and we there-
fore, log2 transformed data in order to approach normality.
The LBM distribution did not display any skewed distribution
and was not transformed.
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Biomarkers data from the control group and the HNSCC
subjects were compared at baseline in a mixed models anal-
ysis of variance. In this analysis, all HNSCC subjects were
pooled, as they were not separated by different intervention
courses yet and thus biologically comparable.
For changes over time, biomarker measurements were
expressed as ratios relative to the baseline and subjected
to two-way mixed models of analysis. Where signiﬁcant
group effects were seen, manual testing, subjected to
Bonferroni correction was performed. ProC3, IC6, and
IC6/C6M were correlated using linear regression to LBM
assessed by DXA providing Pearson correlation coefﬁcients.
The C6M before and after resistance exercise periods were
correlated to the change in LBM during resistance training
rehabilitation using linear regression in order to identify
whether individual biomarker levels were related to individ-
ual changes in LBM
Data were organized and transformed in Microsoft Excel for
Mac 2011 (Microsoft Corporation, Redmond,WA, USA).The anal-
ysis of variancewas performed in SAS/STAT software package 9.3
(SAS Institute). Correlations and Linear regression was performed
using Prism (v6.00 for Mac and Windows). A signiﬁcance
threshold of 0.05 was selected for statistical testing.
Results
Biomarker levels at baseline
For the purpose of baseline comparisons, we pooled the inter-
vention groups’ baseline measurements prior to statistical
analysis. We found no signiﬁcant differences between the
intervention group and the control group for IC6 and ProC3,
nor for the ratio between IC6 and C6M, whereas for C6M, a
highly signiﬁcant difference (P< 0.001) was observed
(Figure 1).
Biomarker levels across times
In the two-way mixed models analysis, signiﬁcant main ef-
fects for time and borderline signiﬁcant group effects could
be observed for the IC6 biomarker (time: P = 0.0161; group:
P = 0.0569) and the IC6/C6M ratio (time: P = 0.0282; group:
P = 0.0503). However, post hoc testing revealed no signiﬁcant
differences at any particular time points (Figure 2)
Correlation between biomarkers and lean body
mass at baseline
The linear regression analysis revealed signiﬁcant correlations
between IC6 or the IC6/C6M ratio and LBM in the healthy con-
trols (Table 2 and Figure 3). Furthermore, we found a borderline
signiﬁcant (P=0.057) correlation between the ProC3 biomarker
and LBM. However, we found no correlation on either a bio-
marker or an LBM in HNSCC patients at baseline (Tables 2 and 3).
C6M during resistance training periods
As we have previously shown that the C6M biomarker ap-
peared to be related to the rate of LBM regain during remo-
bilization following immobilization, we compared the levels
of the C6M with the exercise-induced changes in LBM.8 We
did this by comparing biomarker levels obtained before and
after the resistance training periods in each group
individually and pooled (T1 and T2 for the EE group and T2
and T3 for DE group) to the change in LBM for the same pe-
riods and found no signiﬁcant correlations (Table 3). It does
not appear as if the C6M biomarker is a biomarker of anabolic
response to resistance training in recovering HNSCC patients.
Discussion
In the present study, we measured biomarker levels in recov-
ering HNSCC patients subjected to resistance training follow-
ing primary treatment as well as in age-matched and gender
matched controls. The purpose was to validate our previously
reported ﬁndings, that is, that certain novel collagen-based
peptide biomarkers are biomarkers of LBM or change herein.
Biomarkers at baseline
We found that levels of the C6M biomarker were signiﬁcantly
higher in HNSCC subjects than in the matched controls, that
is, before they were exposed to resistance training (Figure 1).
Figure 1 Biomarker levels at baseline—HNSCC vs. controls. Back-trans-
former biomarker levels at baseline between the HNSCC intervention
group (pooled, termed ‘HNSCC patients’ in the ﬁgure, n = 41) and the
matched healthy controls (n = 21). Dots represent individual values. An
asterisk (*) denotes signiﬁcant difference between the intervention
group and the control group (P< 0.05). HNSCC, head and neck squa-
mous cell carcinoma.
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In this study design, we cannot determine if this is derived
from muscle or from other bodily compartments. In previous
studies, this biomarker has shown also to be produced during
tissue ﬁbrosis in the lungs or in the liver.14 Therefore, we hy-
pothesize that the elevated levels of the C6M in the interven-
tion groups are consequences of either the disease or the
treatment, rather than due to a contribution from muscle.
Biomarkers across time
The changes in biomarkers across times were of modest mag-
nitudes and manifested as signiﬁcant time effects for IC6 and
IC6/C6M, but upon post hoc analysis, no individual differ-
ences could be observed between time points (Figure 2).
Therefore, we were not able to conﬁrm the part of our hy-
pothesis concerning our biomarkers possible being markers
of change in muscle mass in HNSCC patients.
Biomarker correlations with lean body mass
We have shown that the biomarkers IC6 and ProC3 and the
ratio between IC6 and C6M all correlate with LBM at baseline
in healthy humans of both genders and of ages in the range
27–69 (59 ± 6), but this was not the case in a cohort of recov-
ering HNSCC patients (Figure 3). As for IC6 and ProC3, these
ﬁndings are not only in agreement with our previous ﬁndings
for these biomarkers but also expand the ﬁndings to a group
of both genders and a larger age distribution, as the previous
ﬁnding were conﬁned to healthy young men.7,8 As the ProC3
is the pro-peptide of Type III collagen, it is produced and se-
creted during Collagen III synthesis. Our group has previously
reported that this biomarker correlates with muscle mass in
healthy adults in a steady-state condition.7 This indicates that
a signiﬁcant portion of the ProC3 neoepitope fragment in
serum is possibly derived from continuous Collagen III
Figure 2 Biomarker levels across times and groups. Biomarker levels at all time points expressed as ratios relation to baseline (T1) in early exercise
(EE, n = 20) and delayed exercise (DE, n = 21) groups. Data are shown as geometric means and back-transformed standard error. Bar denotes sig-
niﬁcant time effects (P< 0.05). EE, early exercise; DE, delayed exercise.
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Table 2 Correlation matrix for selected biomarkers vs. LBM at baseline
EE/DE group pooled Control group
n=41 n=21
R2 P R2 P
Log2 ProC3 0.0034 0.717 0.1779 0.057
Log2 IC6 0.0239 0.335 0.2479 0.036*
Log2 IC6/C6M 0.0297 0.288 0.4163 0.007*
The data shown are for the ‘goodness of ﬁt’ coefﬁcients provided
by the linear regression analysis and their respective P-values.
*denotes P< 0.05. EE, early exercise; DE, delayed exercise; LBM,
lean body mass.
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production in muscle. Commercially available radio immuno-
sorbent assays against the same peptide (PIIINP) (but using
different antibodies) have detected increases in response to
testosterone and/or human growth hormone therapy.15–17
As these treatments are known to increase muscle mass
and intramuscular connective tissue in which collagen III is
highly expressed, this substantiates the notion that a signiﬁ-
cant portion of the collagen III propeptide in serum is derived
from muscle. The reason that we could not ﬁnd any correla-
tion between the biomarkers and LBM in the HNSCC subjects
is most likely that either the cancer pathology or treatment
have caused changes in extracellular matrix turnover that
cause changes in the circulating levels of biomarkers that
are separated from LBM or muscle mass.
Biomarker correlations to change in lean body
mass
In our previous studies, we showed that the levels of the C6M
biomarker was inversely related to subsequent LBM regain
during retraining following immobilization.8,18 We compared
the changes in LBM for the resistance training periods with
the C6M levels before and after the corresponding period.
We could not reproduce this ﬁnding in the present study
(Table 3). Several factors may explain this discrepancy: Firstly,
the time frames and sampling time points (3months between
measurements) in the present study could be wrong for this
type of correlation. Secondly, we cannot exclude the possibil-
ity that because the initial study was of a limited sample size,
the correlation between C6M and muscle regain could be a
type II error. This is always a risk when doing correlation anal-
yses on small sample sizes. In conclusion, the current study
does not suggest that this particular cohort C6M is indicative
of subsequent exercise-induced anabolism.
Limitations
Even though Collagen types III and VI have both been shown to
be important constituents of skeletal muscle extracellular ma-
trix, we cannot exclude the possibility that they are derived
from extra-cellular matrix processing in other tissues. This is
most likely also the reason that we did not see any relations
Figure 3 Selected biomarker correlations vs. LBM (control group). Cor-
relations between log2-transformed IC6, ProC3, and IC6/C6M bio-
markers and LBM from healthy controls (n = 21) using a parametric
linear regression, with curves showing the best ﬁts and corresponding
linear regression Pearson correlation coefﬁcients and P-values. EE, early
exercise; DE, delayed exercise; LBM, lean body mass.
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Table 3 Correlation matrix for C6M vs RT-induced change in LBM
EE group
n = 20 R2 P
C6M at T1 (before RT) vs. ΔLBM 0.001 0.896
C6M at T2 (after RT) vs. ΔLBM 0.0097 0.698
DE group
n=21
C6M at T2 (before RT) vs. ΔLBM 0.007 0.764
C6M at T3 (after RT) vs. ΔLBM 0.028 0.551
EE+DE pooled
n=41
C6M before RT vs. ΔLBM 0.003 0.769
C6M after RT vs. ΔLBM 0.017 0.474
Correlation matrix for C6M levels prior to and after RT periods, for
the EE and DE groups as well as for both groups pooled. EE, early
exercise; DE, delayed exercise; LBM, lean body mass.
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between biomarkers and LBM or change thereof in the present
study. This is of course a fundamental issue related to serolog-
ical biomarkers, and this is particularly true for cancer patients
having received chemotherapy and radiotherapy, as both of
these can affect connective tissue turnover and ﬁbrosis
processes, possibly providing new sources of biomarker
peptides for the circulation.19,20 In order to circumvent this
problem, we need to further characterize where and how these
biomarker peptides are produced and metabolized.
The correlations between biomarkers and muscle mass are,
although interesting, probably of limited clinical utility so far,
as more precise methods are available to characterize muscle
mass. Also, the correlations between LBM and the biomarkers
are probably not strong enough to allow for assessing changes
in muscle mass from repeated biomarker samplings, as the
correlation between the biomarker is not strong enough to
reveal small differences in muscle mass.
It should also be stated the DAHANCA 25B is not a big co-
hort, and as we did not perform a power analysis, we cannot
exclude the possibility that a larger cohort would have re-
vealed correlations that we did not ﬁnd in this study.
In our study the experiment was conducted at two sepa-
rate sites, using two separate DXA scanners. It has previously
been reported that comparing results between DXA scanners
without compensation for this difference is problematic at
best.21,22 However, a newer study comparing similar types
of scanner with those used in this study showed the discrep-
ancies in measured LBM between them to be of a statistically
insigniﬁcant size.23
Conclusion
In conclusion, we were able to reproduce and thus validate
part of our previous ﬁndings in showing that the ProC3 and
IC6 biomarkers are biomarkers of LBM in healthy adults,
thereby expanding them to both genders and to a wider
age range. However, we were not able to show that they
are biomarkers of LBM in recovering head and neck cancer
patients. Nor, were we able to conﬁrm our hypothesis that
C6M would be a biomarker of anabolic response to training
during recovery from head and neck cancer.
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